Karyopharm Therapeutics Inc. reaffirmed earnings guidance for the full year of 2024. For the year, the company expects total revenue to be in the range of $140.0 million to $160.0 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.